Summit Therapeutics Inc (SMMT)

Sep 24, 2026

Summit Therapeutics Inc. (SMMT) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 24, 2026

Sep 24, 2026

Summit Therapeutics plc (SMMT) stock price, news, quote and history - Yahoo Finance UK

Sep 24, 2026

Sep 24, 2026

Summit Therapeutics Inc. (SMMT) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore

Sep 24, 2026

Sep 23, 2026

Summit Therapeutics Inc. (SMMT) stock price, news, quote and history - Yahoo Finance Australia

Sep 23, 2026

Sep 22, 2026

Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Nigeria

Sep 22, 2026

Sep 22, 2026

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESM - BioSpace

Sep 22, 2026

Sep 22, 2026

Barclays Keeps Their Hold Rating on Summit Therapeutics (SMMT) - The Globe and Mail

Sep 22, 2026

Sep 21, 2026

Summit Therapeutics (SMMT): Time To Take A Look Ahead Of The FDA Decision - RTTNews

Sep 21, 2026

Sep 21, 2026

Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18 - Moomoo

Sep 21, 2026

Sep 21, 2026

Summit Therapeutics Inc. (SMMT) Investor Outlook: A 61.77% Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews

Sep 21, 2026

Sep 20, 2026

Summit Therapeutics (SMMT) Shows Promise in Lung Cancer Trial but Faces Valuation Challenges - GuruFocus

Sep 20, 2026

Sep 17, 2026

Summit Therapeutics: It’s Okay Not To Have An Answer (NASDAQ:SMMT) - Seeking Alpha

Sep 17, 2026

Sep 16, 2026

Ivonescimab vs Pembrolizumab: New Data From HARMONi-2 in Advanced NSCLCSummit Therapeutics - Oncodaily

Sep 16, 2026

Sep 16, 2026

Is Summit Therapeutics (SMMT) Below Fair Value On New Ivonescimab Survival Data? - finance.yahoo.com

Sep 16, 2026

Sep 15, 2026

Form 8K Summit Therapeutics PLC For: 15 September By Investing.com - Investing.com UK

Sep 15, 2026

Sep 14, 2026

SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill

Sep 14, 2026

Sep 14, 2026

Form 8K Summit Therapeutics PLC For: 14 September By Investing.com - Investing.com UK

Sep 14, 2026

Sep 14, 2026

Why Is Summit Therapeutics Stock Gaining Monday? - Benzinga

Sep 14, 2026

Sep 13, 2026

Summit Therapeutics (SMMT) Shows Promising Trial Results but Faces Valuation Challenges - GuruFocus

Sep 13, 2026

Sep 13, 2026

Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial (SMMT:NASDAQ) - Seeking Alpha

Sep 13, 2026

Sep 13, 2026

Summit Therapeutics (SMMT) Gains Attention as Phase III Trial Da - GuruFocus

Sep 13, 2026

Sep 13, 2026

Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Sep 13, 2026

Sep 12, 2026

Why Is SMMT Stock Tumbling Today? - Stocktwits

Sep 12, 2026

Sep 10, 2026

Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com South Africa

Sep 10, 2026

Sep 09, 2026

Summit Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com

Sep 09, 2026

Sep 09, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 09, 2026

Sep 09, 2026

Summit Therapeutics shares gain after Jefferies upgrades stock to Buy - Yahoo Finance

Sep 09, 2026

Sep 09, 2026

Summit Therapeutics stock surges on Jefferies upgrade to buy By Investing.com - Investing.com Canada

Sep 09, 2026

Sep 07, 2026

Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 61.45% Upside - DirectorsTalk Interviews

Sep 07, 2026

Sep 07, 2026

Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress - finance.yahoo.com

Sep 07, 2026

Sep 05, 2026

Why Is SMMT Stock Surging Over 10% In Overnight Trading? - Stocktwits

Sep 05, 2026

Sep 04, 2026

Ivonescimab Demonstrates an Overall Survival Benefit in Advanced NSCLCSummit Therapeutics - Oncodaily

Sep 04, 2026

Sep 04, 2026

Why Summit Therapeutics (SMMT) Is Up 19.5% After New Ivonescimab Phase III Survival DataAnd What's Next - simplywall.st

Sep 04, 2026

Sep 03, 2026

Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S. (SMMT) - Seeking Alpha

Sep 03, 2026

Sep 03, 2026

Why is Summit Therapeutics stock surging today? By Investing.com - Investing.com South Africa

Sep 03, 2026

Sep 03, 2026

Summit's Ivonescimab Beats Merck's Keytruda on Survival in Chinese Lung Cancer Trial - finance.biggo.com

Sep 03, 2026

Sep 03, 2026

Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug - Barron's

Sep 03, 2026

Sep 03, 2026

Why Is Summit Therapeutics Stock Soaring Today?Summit Therapeutics (NASDAQ:SMMT) - Benzinga

Sep 03, 2026

Sep 03, 2026

Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - Benzinga

Sep 03, 2026

Sep 03, 2026

Why is Summit Therapeutics stock surging today? - investing.com

Sep 03, 2026

Sep 03, 2026

Summit Therapeutics stock rises on positive survival data By Investing.com - Investing.com Nigeria

Sep 03, 2026

Sep 03, 2026

Ivonescimab shows statistically significant OS vs pembrolizumab in HARMONi-2, Summit Therapeutics notes - TradingView

Sep 03, 2026

Sep 03, 2026

Summit Therapeutics stock rises on positive survival data - Investing.com

Sep 03, 2026

Sep 03, 2026

November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet - Seeking Alpha

Sep 03, 2026

Sep 02, 2026

Summit Therapeutics (SMMT) Gains on Positive Phase III Trial Res - GuruFocus

Sep 02, 2026

Sep 02, 2026

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China - Yahoo Finance

Sep 02, 2026

Sep 01, 2026

Cantor Fitzgerald reiterates Summit Therapeutics stock rating - Investing.com

Sep 01, 2026